Therapeutic use of somatostatin peptides
AssigneeNovartis AG
InventorsEric Paul Krenning, Steven Willem Jan Lamberts
Life of this patent
Estimating the term…
Abstract
The invention relates to a new pharmaceutical use of somatostatin peptides comprising on the terminal amino group a polyamino polycarboxylic group, in free form or in a pharmaceutically acceptable salt form, particularly in the manufacture of a medicament for treating disorders with an aetiology comprising or associated with excess of GH-secretion.
Claims23
A method for treating disorders with an aetiology comprising or associated with excess GH-secretion, for treating gastro-intestinal disorders, for inhibiting proliferation and/or keratinisation of epidermal cells, or for treating degenerative senile dementia in a subject in need of such a treatment, which comprises administering to said subject an effective amount for treating said disorders of a somatostatin peptide modified at the terminal amino group by a polyaminopolycarboxylic group attached to the terminal amino group by an amide bond, in free form or in pharmaceutically acceptable salt form.
A method for the in vivo detection of tuberculosis, sarcoidosis, malignant lymphoma, Merkel cell tumor of the skin, osteosarcoma, focal lymphocytic reaction, localized autoimmune disease, and organ rejection after transplantation in a subject in need thereof, which comprises a) administering to said subject a labeled somatostatin peptide modified at the terminal amino group by a polyaminopolycarboxylic group attached to the terminal amino group bv an amide bond, in free form or in pharmaceutically acceptable salt form and labeled with a .gamma.- or positron-emitting radionuclide in an amount effective for said in vivo detection and b) recording the localization of the receptors targeted by said labeled somatostatin peptide.
A method for treating malignant lymphoma, Merkel cell tumor of the skin, or osteosarcoma in a subject in need of such a treatment which comprises administering to said subject a therapeutically effective amount for said treatment of a labeled somatostatin peptide modified at the terminal amino croup by a polyaminopolycarboxylic group attached to the terminal amino group by an amide bond, in free form or in pharmaceutically acceptable salt form and labeled with a .alpha.- or .beta.-emitting radionuclide.
Dependencies are inferred from the claim text.